Statement Of Cash Flows [Abstract]

PCI Biotech Holding - Filing #5867918

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	- NOK	16 417 NOK	—	16 417 NOK	- NOK	- NOK	20 315 NOK	20 315 NOK	—	- NOK	—
Adjustments to reconcile profit (loss) [abstract]
Adjustments for increase (decrease) in trade accounts payable	—	1 010 NOK	—	—	—	—	—	217,000 NOK	—	—	—
Adjustments for depreciation and amortisation expense	—	303,000 NOK	—	—	—	—	—	371,000 NOK	—	—	—
Adjustments for share-based payments	—	827,000 NOK	—	—	—	—	—	1 955 NOK	—	—	—
Other adjustments to reconcile profit (loss)	—	1 727 NOK	—	—	—	—	—	838,000 NOK	—	—	—
Interest paid, classified as operating activities	—	- NOK	—	—	—	—	—	1,000 NOK	—	—	—
Interest received, classified as operating activities	—	1 596 NOK	—	—	—	—	—	2 045 NOK	—	—	—
Cash flows from (used in) operating activities	—	13 758 NOK	—	—	—	—	—	14 970 NOK	—	—	—
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) investing activities	—	- NOK	—	—	—	—	—	- NOK	—	—	—
Cash flows from (used in) financing activities [abstract]
Payments of lease liabilities, classified as financing activities	—	357,000 NOK	—	—	—	—	—	442,000 NOK	—	—	—
Cash flows from (used in) financing activities	—	357,000 NOK	—	—	—	—	—	442,000 NOK	—	—	—
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes	—	14 115 NOK	—	—	—	—	—	15 412 NOK	—	—	—
Cash and cash equivalents	—	—	27 069 NOK	—	—	—	—	—	41 184 NOK	—	56 596 NOK